238 related articles for article (PubMed ID: 30498897)
21. IL13RA2 targeted alpha particle therapy against glioblastomas.
Sattiraju A; Solingapuram Sai KK; Xuan A; Pandya DN; Almaguel FG; Wadas TJ; Herpai DM; Debinski W; Mintz A
Oncotarget; 2017 Jun; 8(26):42997-43007. PubMed ID: 28562337
[TBL] [Abstract][Full Text] [Related]
22. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
24. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
[TBL] [Abstract][Full Text] [Related]
25. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
26. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
27. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract][Full Text] [Related]
29. Targeted alpha therapy with 213Bi.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
[TBL] [Abstract][Full Text] [Related]
30. Targeted alpha therapy for glioblastoma.
Kunikowska J; Morgenstern A; Pełka K; Bruchertseifer F; Królicki L
Front Med (Lausanne); 2022; 9():1085245. PubMed ID: 36590948
[TBL] [Abstract][Full Text] [Related]
31. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
32. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
[TBL] [Abstract][Full Text] [Related]
34. Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with
Majkowska-Pilip A; Koźmiński P; Wawrzynowska A; Budlewski T; Kostkiewicz B; Gniazdowska E
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301182
[TBL] [Abstract][Full Text] [Related]
35. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
36. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
37. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
Jurcic JG; Rosenblat TL
Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of [
Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
[TBL] [Abstract][Full Text] [Related]
39. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme.
Combs SE; Gutwein S; Thilmann Ch; Huber P; Debus J; Schulz-Ertner D
J Neurooncol; 2005 Sep; 74(2):167-71. PubMed ID: 16193388
[TBL] [Abstract][Full Text] [Related]
40. Re-irradiation with radiosurgery for recurrent glioblastoma multiforme.
Torok JA; Wegner RE; Mintz AH; Heron DE; Burton SA
Technol Cancer Res Treat; 2011 Jun; 10(3):253-8. PubMed ID: 21517131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]